The researchers concluded that rituximab should be considered as a preferred biologic treatment for rheumatoid arthritis (RA) therapy, though treatment of RA with any biologic medication improved quality of life significantly.
A recent study, based on real-world experience in Bulgaria, looked to compare the quality of life (QOL) benefits and the cost of biologic therapeutic options for the treatment of rheumatoid arthritis (RA).
In the observational study, researchers enrolled 124 patients treated with biological medicines after receiving prior treatment with conventional drugs from 2012 to 2016 at a university hospital in Bulgaria. QOL was assessed through the European Quality 5-Dimensions (EQ5D) questionnaire at the beginning of therapy, after 6 months, and 1 year.
Physicians were able to choose the biologic medicine prescribed to their patient based on clinical status of the patients and the available medicines on the hospital’s reimbursement list. Patients in the study took the following therapies: tocilizumab (n = 30), certolizumab pegol (n = 16), golimumab (n = 22), etanercept (n = 20), adalimumab (n = 20), and rituximab (n = 16).
Click here to read more about biologic therapies in RA.
To evaluate the cost effectiveness of each respective product, researchers built a decision-tree model using software to compare the yearly pharmacotherapy cost with the changes in EQ5D scores after 1 year of biologic therapy.
Through the evaluation, researchers confirmed that the QOL improvement produced by biologic therapy is statistically significant. Specifically, as measured by EQ5D, QOL improves quickly at the beginning of therapy and subsequently slows down toward the end of 1 year of therapy.
However, though each drug was found to improve the QOL of RA patients, only rituximab was identified to be cost-effective.
“Biological medicines appear not to be cost-effective due to their high incremental cost-effectiveness ratio,” the authors noted. Rituximab’s incremental cost-effectiveness ratio falls close to being 3 time the gross domestic product per capita threshold.
The researchers concluded that rituximab should be considered as a preferred biologic treatment for RA therapy, though treatment of RA with any biologic medication improves quality of life significantly.
Reference
Boyadzieva V, Stoilov N, Stoilov R, et al. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol. 2018;9:794. doi: 10.3389/fphar.2018.00794.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.